Janux Therapeutics (JANX) Revenue & Revenue Breakdown
Janux Therapeutics Revenue Highlights
Latest Revenue (Y)
$8.08M
Latest Revenue (Q)
$1.25M
Janux Therapeutics Revenue by Period
Janux Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $8.08M | -6.14% |
| 2022-12-31 | $8.61M | 136.79% |
| 2021-12-31 | $3.64M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Janux Therapeutics generated $8.08M in revenue during NA 2023, up -6.14% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Janux Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $1.25M | -49.13% |
| 2023-12-31 | $2.46M | -2.22% |
| 2023-09-30 | $2.52M | 138.13% |
| 2023-06-30 | $1.06M | -48.39% |
| 2023-03-31 | $2.05M | -28.01% |
| 2022-12-31 | $2.85M | 56.92% |
| 2022-09-30 | $1.81M | -23.34% |
| 2022-06-30 | $2.37M | 48.84% |
| 2022-03-31 | $1.59M | -1.67% |
| 2021-12-31 | $1.62M | 39.43% |
| 2021-09-30 | $1.16M | 140.46% |
| 2021-06-30 | $482.00K | 26.84% |
| 2021-03-31 | $380.00K | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Janux Therapeutics generated $1.25M in revenue during Q1 2024, up -49.13% compared to the previous quarter, and up 44.01% compared to the same period a year ago.
Janux Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HRMY | Harmony Biosciences | $582.02M | $172.81M |
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| ADAG | Adagene | $18.11M | $833.34K |
| JANX | Janux Therapeutics | $8.08M | $1.25M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| MNOV | MediciNova | $1.00M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| ANTX | AN2 Therapeutics | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| CSBR | Champions Oncology | - | $12.02M |
JANX Revenue FAQ
What is Janux Therapeutics’s yearly revenue?
Janux Therapeutics's yearly revenue for 2023 was $8.08M, representing a decrease of -6.14% compared to 2022. The company's yearly revenue for 2022 was $8.61M, representing an increase of 136.79% compared to 2021. JANX's yearly revenue for 2021 was $3.64M, representing an increase of 100.00% compared to 2020.
What is Janux Therapeutics’s quarterly revenue?
Janux Therapeutics's quarterly revenue for Q1 2024 was $1.25M, a -49.13% decrease from the previous quarter (Q4 2023), and a -38.87% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $2.46M, a -2.22% decrease from the previous quarter (Q3 2023), and a -13.50% decrease year-over-year (Q4 2022). JANX's quarterly revenue for Q3 2023 was $2.52M, a 138.13% increase from the previous quarter (Q2 2023), and a 38.83% increase year-over-year (Q3 2022).
What is Janux Therapeutics’s revenue growth rate?
Janux Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 122.24%, and for the last 5 years (2019-2023) was 0%.